ERBB2 and breast cancer: More studies have shown that APCs readily take the immunogenic molecules from the displaying phage, process and present them on MHC I and MHC II molecules to induce higher immune responses compared with soluble antigens with no carriers (74).A particularly effective immune strategy to induce T-cell responses against tumor antigens is to use DCs loaded with the tumor antigen.It is feasible and safe to generate and administer HER2-loaded DCs to patients with advanced HER2/neu-expressing malignancies and high-risk breast cancer (75).